No Data
Alice: Shanghai Alice Pharmaceutical Technology Co., Ltd. 2024 Annual Results Forecast
Shanghai Alice Pharmaceutical Technology Co., Ltd. 2024 Annual Results Forecast
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): Expected net profit increase of 121.99% for the year 2024.
On January 20, Gelonghui reported that Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced its performance forecast for 2024. The company expects to achieve a Net income attributable to the parent company of 1.43 billion yuan in 2024, an increase of 121.99% year-on-year. The company expects to achieve a Net income attributable to the parent company after deducting non-recurring gains and losses of 1.36 billion yuan in 2024, an increase of 124.35% year-on-year. The company's revenue, Net income attributable to the parent company, and Net income attributable to the parent company after deducting non-recurring gains and losses are all expected to see significant growth compared to the same period last year.
Allist Pharma Gets Nod to Trial Vometinib Mesylate Tablets
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): The new indication of fumetinib has obtained the approval notice for clinical drug trials.
On January 17, Gelonghui reported that Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that it has recently received the "Notice of Approval for Clinical Trials" issued by the National Medical Products Administration, approving the clinical research for the new indication of Furmetin Tablets (referred to as "Furmetin"). Furmetin is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), a class 1 small molecule targeted drug developed by the company. Furmetin is a highly selective, irreversible third-generation EGFR-TKI, mainly used for the treatment of non-small-cell lung cancer with EGFR mutations.
China Galaxy Securities: A review of the fifth set of standards on the Star has significantly boosted investment in the pharmaceutical industry.
Future reforms in diversified payment for commercial insurance are expected to bring marginal improvements from a policy perspective, and there are good long-term investment opportunities in pharmaceutical innovation and related industries.
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Shareholders Might Be Looking For Exit